advisory panels

FDA Panel Votes 8-7 in Favor of Mallinckrodt's HRS-1 Drug
FDA Panel Votes 8-7 in Favor of Mallinckrodt's HRS-1 Drug
BioSpace
Mallinckrodt
FDA
terlipressin
HRS-1
advisory panels
Flag link:
FDA panel to review GlaxoSmithKline multiple myeloma drug next month
FDA panel to review GlaxoSmithKline multiple myeloma drug next month
MedCity News
belantamab mafodotin
GSK
Multiple Myeloma
FDA
advisory panels
Flag link:
FDA moots virtual AdComms but delays GSK, Intercept meetings
FDA moots virtual AdComms but delays GSK, Intercept meetings
Fierce Biotech
FDA
advisory panels
GSK
Intercept Pharma
Flag link:
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
Lilly’s Cyramza closer to first-line lung cancer use after ODAC verdict
Pharmaforum
Eli Lilly
Cyramza
non-small cell lung cancer
FDA
advisory panels
Flag link:
FDA's Advisory Committee to Review Claims That GlaxoSmithKline's Trelegy Ellipta Reduces Mortality
FDA's Advisory Committee to Review Claims That GlaxoSmithKline's Trelegy Ellipta Reduces Mortality
Motley Fool
GSK
FDA
advisory panels
COPD
Trelegy Ellipta
Flag link:
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
pancreatic cancer
FDA
advisory panels
Flag link:
FDA expert panel unanimously recommends approval for Horizon Therapeutics eye drug
FDA expert panel unanimously recommends approval for Horizon Therapeutics eye drug
Endpoints
FDA
advisory panels
Horizon Therapeutics
thyroid eye disease
teprotumumab
Flag link:
What's Next for Amarin's Stock?
What's Next for Amarin's Stock?
Motley Fool
Amarin
Vascepa
FDA
pharma stocks
advisory panels
Flag link:
The future of Vascepa sales, and Amarin, could hinge on next week's panel
The future of Vascepa sales, and Amarin, could hinge on next week's panel
EP Vantage
Amarin
Vascepa
FDA
advisory panels
M&A
Flag link:
FDA Ad Com thumbs down on full Makena approval
FDA Ad Com thumbs down on full Makena approval
Seeking Alpha
Makena
preterm birth
Amag Pharmaceuticals
FDA
advisory panels
Flag link:
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Endpoints
Shionogi
FDA
advisory panels
antibiotics
cefiderocol
UTIs
Flag link:
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
Endpoints
Shionogi
FDA
advisory panels
antibiotics
UTIs
cefiderocol
Flag link:
GSK's oral nicotine spray wins divided FDA panel's backing despite abuse risks
GSK's oral nicotine spray wins divided FDA panel's backing despite abuse risks
Fierce Pharma
GSK
FDA
advisory panels
OTC
Flag link:
An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening
An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening
Stat
FDA
advisory panels
peanut allergy
Aimmune Therapeutics
Palforzia
Flag link:
Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting
Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting
Fierce Pharma
Amarin
Vascepa
advisory panels
FDA
Flag link:
13 Keys to a Successful FDA Advisory Committee Meeting
13 Keys to a Successful FDA Advisory Committee Meeting
RAPS.org
FDA
advisory panels
Flag link:
Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom
Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom
Endpoints
FDA
Amarin
Vascepa
advisory panels
earnings
Flag link:
FDA cancels panel review of Intra-Cellular’s schizophrenia drug, causing shares to tumble
FDA cancels panel review of Intra-Cellular’s schizophrenia drug, causing shares to tumble
Stat
Intra-Cellular Therapies
FDA
advisory panels
schizophrenia
lumateperone
Flag link:
FDA overrides adcomm opinions a fifth of the time, study finds — but why?
FDA overrides adcomm opinions a fifth of the time, study finds — but why?
Endpoints
FDA
advisory panels
Flag link:
U.S. advisory panel stops short of broad recommendations for two common vaccines
U.S. advisory panel stops short of broad recommendations for two common vaccines
Stat
FDA
vaccines
HPV
pneumonia
advisory panels
Merck
Gardasil
Pfizer
Prevnar 13
Flag link:

Pages